Source: Virtual Congress 2021 – Advanced in vitro models for drug discovery



Rating:

Share or cite this content

Citations should be made in the following way:
V. Pitozzi (Parma, Italy), P. Caruso (Parma, Italy), M. Bonatti (Parma, Italy), B. Sotthewes (Leiden, Netherlands), J. Degroot (Leiden, Netherlands), G. Villetti (Parma, Italy), M. Civelli (Parma, Italy), M. Trevisani (Parma, Italy), M. Pittelli (Parma, Italy). Differential effects of Nintedanib and SB525334 in primary human cell-based assays of lungfibrosis. 3696

Member's Comments

No comment yet.

Related content which might interest you: In vitro pharmacological characterization of the potent, lung selective pan-JAK inhibitor TD-8236 Source: International Congress 2019 – Advances in asthma pharmacology Year: 2019 Differential effects of pharmacological leukotriene pathway modulators in a human lung tissue explant model Source: Virtual Congress 2020 – Asthma science: novel targets and mechanisms Year: 2020 Nintedanib mediates effective modulation of relevant pro-fibrotic biomarkers ex vivo Source: International Congress 2019 – Pathogenesis and prognosis of interstitial lung disease of known origin Year: 2019 In vitro and in vivo anti-inflammatory activity of the novel PDE4 inhibitor roflumilast Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001 Synergistic anti-tumor effects of vandetanib, an inhibitor of VEGFR and EGFR tyrosine kinase inhibitor, combined with cytotoxic agents in lung cancer cell lines Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 In vitro anti-inflammatory activity of the new glucocorticoid ciclesonide in human cells Source: Eur Respir J 2001; 18: Suppl. 33, 95s Year: 2001 Protective effect of MAPK inhibitors and budesonide against apoptosis induced by TGF-β in primary cultures of human bronchial epithelial cells Source: Eur Respir J 2003; 22: Suppl. 45, 394s Year: 2003 Selective inhibition of COX-2 by celecoxib exerts negative effects on endothelial progenitor cell proliferation and stimulates apoptosis in vitro Source: Eur Respir J 2005; 26: Suppl. 49, 368s Year: 2005 P38 signalling pathway in primary cultures of human bronchial epithelial cells: effects of transforming growth factor-β and pharmacological modulation by budesonide Source: Eur Respir J 2002; 20: Suppl. 38, 571s Year: 2002 LSC - 2017 - RNA-Seq analysis reveals major differences between the effects of rapamycin and dual mTORC1/2 inhibition during TGFß1-induced myofibroblast differentiation Source: International Congress 2017 – Cellular signalling pathways in pulmonary fibrosis Year: 2017 Targeting of STAT3 and survivin with TG101209, a novel JAK2 inhibitor, enhances radiotherapy in lung cancer models Source: Annual Congress 2010 - New insights in the pathology of lung cancer Year: 2010 Fast, efficient and realistic in vitro delivery of inhaled drugs to pulmonary cells: Application to the proteasome inhibitor bortezomib Source: Annual Congress 2013 –Cutting edge: drug delivery to the airways Year: 2013 Differential effects of pirfenidone and nintedanib on mouse alveolar epithelial organoids Source: Virtual Congress 2020 – Elucidating the mechanisms underlying lung repair and exploring therapeutic strategies in vitro Year: 2020 Comparison of in-vitro anti-fibrotic effects of pirfenidone and nintedanib Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia Year: 2019 Pirfenidone induced inhibition of p38 downregulates procoagulant microparticle generation by human alveolar epithelia cells Source: International Congress 2016 – Translational studies in lung disease Year: 2016 In vitro and in vivo pharmacological profile of RP6503, a novel dual PI3K Δ/gamma inhibitor, in pulmonary disease systems Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013 Effects of CHF6297, a potent and selective p38a MAPK inhibitor, in murine models of steroid resistant lung inflammation Source: International Congress 2017 – Towards new anti-inflammatory and anti-fibrotic agents Year: 2017 Synergistic therapy for NSCLC: Additive preclinical efficacy of interleukin-6 inhibitor madindoline A with crizotinib Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Anti-oxidative and anti-inflammatory effects of Xanthorrhizol on aeroallergens-induced biological responses in vitro and ex vivo Source: International Congress 2019 – Airway inflammation: pharmacological mechanisms and novel targets Year: 2019 Identification of mechanism-specific biomarkers to guide development of the lung-selective inhaled pan-JAK inhibitor TD-8236 Source: Virtual Congress 2020 – Asthma science: novel targets and mechanisms Year: 2020